Scipher Medicine
Helping Patients and Payers by Holding Big Pharma Accountable

Alif Saleh, CEO of Scipher Medicine isn’t one to mince words.

225 million people are annually prescribed drugs to which they don’t respond. For example, anti-TNF drugs Humira, Enbrel, and Remicade cost payers $33 billion per year, yet have limited effect in 65% of patients who take them. Yet pharmaceutical companies continue to advertise these drugs to patients with  Rheumatoid Arthritis, Inflammatory Bowel Disease and other autoimmune conditions knowing full well, they won’t help most of the people who take them.

“Somebody needs to ensure that patients are prescribed drugs that work, from day one.”

That somebody is Scipher Medicine. 

Founded by Dr. Joe Loscalzo and Dr. Albert-Laszlo Barabasi, Scipher has been built to answer the question that’s been haunting modern medicine for decades: Why do some patients

respond to certain drugs, while others don’t? 

Many hoped once we mapped the human genome, the answer to that question would become clear. Unfortunately the answer wasn’t that simple. The answer lies deeper within us than our DNA. Understanding disease happens at the protein level which is infinitely more complex. So they spent 10 years building the most accurate map ever created of human biology – the Human Interactome.  It explains how proteins interact with each other to cause specific diseases. This provides the wiring diagram needed to interpret dynamic molecular data from patients to determine an individual’s unique disease biology. 

Altogether the team mapped over 19,000 proteins in human cells and all the ways they interact with each other. Combined with the power of network science with artificial intelligence the company has developed a simple blood test that determine which drug a patient will respond to across a vast number of conditions. 

This is great news for patients, physicians, and insurance companies who, even with the advances that have been made in biological sciences, have had to resort to trial and error when it comes to selecting and prescribing medication. Try something for months, if it works, great. If not, move on to the next drug and hope for the best. But that will all change very soon thanks to Scipher’s pioneering work in precision medicine.

Scipher is launching its diagnostic platform starting with autoimmune diseases, a $19 billion market including Rheumatoid Arthritis, Ulcerative Colitis, Crohn’s Disease, and Multiple Sclerosis. This will save insurance companies billions of dollars by ensuring patients are prescribed optimal treatment from day one.

Their technology is a disease agnostic platform that can be used to develop drug response tests for multiple disease indications, starting with autoimmune diseases.

Contact FORCE Family Office CEO, Steven Saltzstein to arrange a meeting with Alif Saleh and learn more about how Scipher Medicine’s unique approach to improving outcomes and save billions in health care costs in the coming years.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.